211 related articles for article (PubMed ID: 23982600)
21. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma.
Jamieson NB; Mohamed M; Oien KA; Foulis AK; Dickson EJ; Imrie CW; Carter CR; McKay CJ; McMillan DC
Ann Surg Oncol; 2012 Oct; 19(11):3581-90. PubMed ID: 22555345
[TBL] [Abstract][Full Text] [Related]
22. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; McMillan DC; Elsberger B; Going JJ; Orange C; Mallon E; Doughty JC; Edwards J
Br J Cancer; 2012 Jan; 106(2):383-8. PubMed ID: 22251968
[TBL] [Abstract][Full Text] [Related]
23. The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer.
Mohammed ZM; Going JJ; Edwards J; McMillan DC
Cancer Treat Rev; 2012 Dec; 38(8):943-55. PubMed ID: 22651904
[TBL] [Abstract][Full Text] [Related]
24. Lymphocyte subsets contribute to the degree of lobulitis and ductitis in sclerosing lymphocytic lobulitis of the breast.
Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
J Clin Pathol; 2016 Jun; 69(6):527-32. PubMed ID: 26582743
[TBL] [Abstract][Full Text] [Related]
25. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
26. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
27. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
28. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
29. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma.
Kustic D; Lovasic F; Belac-Lovasic I; Avirovic M; Ruzic A; Petretic-Majnaric S
Rev Med Chil; 2019 May; 147(5):557-567. PubMed ID: 31859887
[TBL] [Abstract][Full Text] [Related]
30. Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma.
Crombie N; Rampaul RS; Pinder SE; Elston CW; Robertson JF; Ellis IO
Br J Surg; 2001 Oct; 88(10):1324-9. PubMed ID: 11578285
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations.
Hussein MR; Hassan HI
J Clin Pathol; 2006 Sep; 59(9):972-7. PubMed ID: 16935972
[TBL] [Abstract][Full Text] [Related]
32. Relationship between parameters from virtual touch tissue quantification (VTQ) imaging with clinicopathologic prognostic factors in women with invasive ductal breast cancer.
Xie J; Wu R; Xu HX; Yao MH; Xu G
Int J Clin Exp Pathol; 2014; 7(10):6644-52. PubMed ID: 25400743
[TBL] [Abstract][Full Text] [Related]
33. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
[TBL] [Abstract][Full Text] [Related]
34. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status.
Blackwell K; Haroon Z; Broadwater G; Berry D; Harris L; Iglehart JD; Dewhirst M; Greenberg C
J Clin Oncol; 2000 Feb; 18(3):600-8. PubMed ID: 10653875
[TBL] [Abstract][Full Text] [Related]
35. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer.
Mohammed ZM; Going JJ; McMillan DC; Orange C; Mallon E; Doughty JC; Edwards J
Histopathology; 2012 Oct; 61(4):675-84. PubMed ID: 22747525
[TBL] [Abstract][Full Text] [Related]
36. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
37. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
38. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
[TBL] [Abstract][Full Text] [Related]
39. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
40. Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers.
Mujtaba SS; Ni YB; Tsang JY; Chan SK; Yamaguchi R; Tanaka M; Tan PH; Tse GM
Ann Surg Oncol; 2013 Sep; 20(9):2842-9. PubMed ID: 23539156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
